Welcome to our dedicated page for Pmv Pharmaceuticals SEC filings (Ticker: PMVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PMV Pharmaceuticals filings document a clinical-stage precision oncology company focused on small molecule therapies targeting p53. The company’s Form 8-K reports disclose operating results, financial condition updates, Regulation FD materials, and rezatapopt clinical disclosures from the PYNNACLE study in tumors with a TP53 Y220C mutation.
Proxy materials describe annual meeting matters, board composition, stockholder voting procedures, and governance practices. The filing record also identifies PMV’s Nasdaq-listed common stock and includes risk and forward-looking-statement disclosures tied to drug development, regulatory pathways, capital resources, and clinical-stage biotechnology operations.
PMV Pharmaceuticals director Laurie Stelzer received a grant of stock options to acquire 42,000 shares of common stock. The options have an exercise price of $1.19 per share and expire on June 4, 2036. All 42,000 options vest on the earlier of June 4, 2027 or the date of the company’s next annual stockholder meeting. Following this award, Stelzer holds 42,000 options directly, reflecting a compensation-related grant rather than any open-market share purchase or sale.
PMV Pharmaceuticals, Inc. director Arnold J. Levine received a grant of stock options covering 42,000 shares of Common Stock at an exercise price of $1.1900 per share. These options expire on June 4, 2036 and vest on the earlier of June 4, 2027 or the issuer's next annual meeting of stockholders, leaving him with 42,000 options following the grant.
PMV Pharmaceuticals director Carol Giltner Gallagher reported option grants and internal transfers involving 42,000-share stock options. She received a stock option for 42,000 shares of common stock at an exercise price of $1.19 per share, expiring on June 4, 2036.
According to a footnote, these options vest on the earlier of June 4, 2027 or the issuer’s next annual meeting of stockholders. The filing also shows bona fide gifts moving options covering a total of 84,000 underlying shares, including a transfer to The Gallagher Revocable Trust dated May 10, 2011, for which she serves as trustee. These are non-market, gift and grant transactions rather than open-market buys or sells.
PMV Pharmaceuticals director Kirsten Flowers received a stock option grant covering 42,000 shares of common stock. The options have an exercise price of $1.19 per share and expire on June 4, 2036. These options vest on the earlier of June 4, 2027 or the date of the company’s next annual stockholder meeting.
PMV Pharmaceuticals director Charles M. Baum received a grant of stock options covering 42,000 shares of common stock. The options have an exercise price of $1.19 per share and expire on June 4, 2036. They vest on the earlier of June 4, 2027 or the company’s next annual stockholder meeting. Following this award, Baum holds 42,000 stock options directly.
PMV Pharmaceuticals, Inc. reported the results of its 2026 virtual annual meeting of stockholders. Stockholders elected two Class III directors: David H. Mack, Ph.D. received 15,693,907 votes for and 6,248,461 withheld, while Laurie Stelzer received 11,261,111 votes for and 10,681,257 withheld. Each will serve until the 2029 annual meeting, subject to earlier death, resignation or removal.
Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 15,015,578 votes for, 6,468,718 against, 458,072 abstentions and 6,975,412 broker non-votes. They also ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, by 28,379,108 votes for, 536,302 against and 2,370 abstentions.
PMV Pharmaceuticals, Inc. Amendment No. 4 to a Schedule 13G/A reports beneficial ownership stakes held by Euclidean Capital and affiliated reporting persons. Euclidean Capital LLC and affiliated individuals/entities report 2,627,643 shares (representing 4.9%) of Common Stock.
The filing shows additional reported holdings: Greenland NFP B Ltd. 1,300,818 shares (2.4%), Greenland A LLC 346,884 shares (0.7%), and Symmetry Group Ltd. 247,203 shares (0.5%). The percentages are calculated using 53,331,766 shares outstanding as of May 12, 2026, as reported in the issuer's Form 10-Q.
PMV Pharmaceuticals reported another quarter of operating losses as it advances its lead cancer drug rezatapopt. For the three months ended March 31, 2026, the company posted a net loss of $18.0 million, similar to the prior-year loss of $17.4 million, as it remains in clinical development with no product revenue.
Research and development expense fell to $15.3 million from $17.4 million, mainly from lower contract research costs on rezatapopt, while general and administrative expense declined to $3.7 million. Interest income decreased to $1.0 million from $1.9 million due to lower balances and rates.
Cash, cash equivalents, and marketable securities totaled $93.5 million, and management believes this will fund operations until the end of the second quarter of 2027. The company highlighted ongoing pivotal Phase 2 work in the PYNNACLE trial and noted that rezatapopt received Orphan Drug Designation in March 2026 for TP53 Y220C–positive ovarian, fallopian tube, and primary peritoneal cancer, with plans to file a New Drug Application in the first quarter of 2027.
PMV Pharmaceuticals reported first quarter 2026 results and highlighted progress for its lead candidate rezatapopt. The company ended March 31, 2026 with $93.5 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into the end of the second quarter of 2027. Net loss was $18.0 million, or $0.34 per share, roughly in line with the prior year as both research and development and general and administrative expenses declined.
Clinically, updated Phase 2 PYNNACLE data in platinum‑resistant/refractory ovarian cancer with TP53 Y220C mutations showed an overall response rate of 44% (32/72) by RECIST 1.1, rising to 46% (34/74) including two additional unconfirmed partial responses, with a median response duration of 8.2 months. Rezatapopt received U.S. FDA Orphan Drug Designation for TP53 Y220C‑positive ovarian, fallopian tube, and primary peritoneal cancers, and PMV plans to submit a New Drug Application for this ovarian cancer indication in the first quarter of 2027.
PMV Pharmaceuticals, Inc. Amendment No. 3 to a Schedule 13G/A reports that Sio Capital Management, LLC beneficially owned 3,076,580 shares of common stock, representing 5.77% of the class. The filing states these shares are held with shared voting and dispositive power as of March 31, 2026. The filing cites 53,329,392 shares outstanding as of March 6, 2026 from the issuer's Form 10-K. The statement is signed by the Reporting Person's Chief Compliance Officer on May 4, 2026.